These are top 10 stocks traded on the Robinhood UK platform in July
Eric Shroff, Senior Vice President of Abbott Laboratories (NYSE:ABT), recently sold 562 shares of the company’s common stock. The transaction, which took place on March 3, 2025, was executed at a price of $138.17 per share, amounting to a total sale value of $77,651. The sale occurs as Abbott, with its substantial $243 billion market cap, trades near its 52-week high of $141.23.
Following the transaction, Shroff retains ownership of 31,970 shares in Abbott Laboratories. The sale was conducted as a direct ownership transaction, as indicated in the filing. InvestingPro analysis shows Abbott’s stock has demonstrated strong momentum, with a notable 22.9% return over the past six months.
This update provides insight into the recent trading activities of Abbott’s executive team, reflecting a minor adjustment in Shroff’s holdings within the company. According to InvestingPro, which offers 15+ additional investment insights for Abbott, the stock is currently trading above its Fair Value, with technical indicators suggesting overbought conditions.
In other recent news, Abbott Laboratories has been the focus of several noteworthy developments. Barclays (LON:BARC) has raised its price target for Abbott to $158, maintaining an Overweight rating, following an updated financial outlook and revised earnings estimates. Despite challenges from foreign exchange rates and tax rates, Abbott has increased its gross margin expectations and set a 2025 earnings per share growth guidance of 10%. Similarly, UBS has lifted its price target for Abbott to $148, reiterating a Buy rating, reflecting confidence in the company’s projected organic sales growth and margin improvements.
Bernstein has also increased its price target for Abbott to $138, citing strong performance in the Medical (TASE:BLWV) Devices segment, with a notable 14% organic growth. Abbott’s collaboration with Cadrenal Therapeutics for a clinical trial involving the HeartMate 3™ LVAD is another significant development. This partnership aims to advance the drug tecarfarin for heart failure patients with LVADs.
These developments come amid a broader market shift towards defensive stocks, with Abbott among those gaining as investors move away from tech stocks due to concerns over China’s DeepSeek AI model. The company’s strategic moves and positive analyst outlooks underscore its potential for continued growth in the medical technology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.